ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI To File Heroin IND For Pain Control; Sen. Cranston To Keynote Meeting On Centers

March 31, 1978

Americans Shouldn’t Take NIH for Granted, Healy Tells NCAB

May 24, 1991

NIH Returns to Play Catch Up “After 16 Costly, Wasteful Days”

October 18, 2013

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010

Who Writes NCI’s bypass Budget anyway>? Editor’s name Revealed

May 14, 1993

OMB Specifies One Year Only Funding for 200 grants Under Supplemental Appropriations Level of 6,200

September 6, 1985